. 2022 Apr 20;21:101426. doi: 10.1016/j.tranon.2022.101426

Table 2.

Monoclonal antibodies approved for the treatment of HNSCC.

S. No.	Drug	Mechanism of action	Year	Disease conditions	Clinical trial	Ref.
1.	Cetuximab	EGFR inhibitor	2006	HNSCC after platinum-based therapy (in combination with radiotherapy)	NCT00004227	[8]
1.	Cetuximab	EGFR inhibitor	2009	R/M HNSCC (in combination with platinum–fluorouracil chemotherapy)	NCT00122460	[68]
2.	Pembrolizumab	PD-1 inhibitor	2016	HNSCC after platinum-based chemotherapy	NCT01848834	[66]
2.	Pembrolizumab	PD-1 inhibitor	2019	Metastatic or unresectable recurrent HNSCC (in combination with platinum and fluorouracil (FU) for all patients and as a single agent for patients whose tumors express PD‑L1)	NCT02358031	[71]
3.	Nivolumab	PD-1 inhibitor	2016	R/M HNSCC with disease progression on or after a platinum-based therapy	NCT02105636	[65]